Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

26.10
+0.12000.46%
Post-market: 26.100.00000.00%19:30 EDT
Volume:1.18M
Turnover:31.06M
Market Cap:4.87B
PE:-7.79
High:26.87
Open:26.22
Low:26.02
Close:25.98
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:6.94
PE(LYR):-7.51

Loading ...

Stock Track | Dyne Therapeutics Soars 5.18% Intraday on Phase 3 Trial Launch and Positive Clinical Data

Stock Track
·
Mar 09

Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen

TIPRANKS
·
Mar 09

Dyne Therapeutics launches Phase 3 HARMONIA trial of z-basivarsen in DM1

Reuters
·
Mar 09

Dyne reports positive 24-month cardiopulmonary results for z-rostudirsen in DELIVER DMD trial

Reuters
·
Mar 09

Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
Mar 09

Dyne Therapeutics Inc - 24-Month Data Show Improved Heart and Lung Function With Z-Rostudirsen in Dmd

THOMSON REUTERS
·
Mar 09

Dyne Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 04

Stock Track | Dyne Therapeutics Plummets 5.08% Intraday Following Analyst Price Target Cuts

Stock Track
·
Mar 03

Dyne Therapeutics (DYN) Gets a Buy from RBC Capital

TIPRANKS
·
Mar 03

Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 03

Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright

TIPRANKS
·
Mar 03

U.S. RESEARCH ROUNDUP-Block, Sherwin-Williams, Union Pacific

Reuters
·
Mar 03

Analysts Offer Insights on Healthcare Companies: American Well (AMWL) and Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 03

Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN)

Simply Wall St.
·
Mar 03

Dyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Earnings Flash (DYN) Dyne Therapeutics Posts Q4 Net Loss $0.76 a Share, vs. FactSet Est of $0.76 Loss

MT Newswires Live
·
Mar 02

Dyne Therapeutics Q4 net loss narrows, beats analyst expectations

Reuters
·
Mar 02

Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate

Benzinga Earnings
·
Mar 02

Dyne Q4 net loss USD 112.0 million on R&D expenses USD 95.4 million for FY 2025 R&D expenses USD 398.3 million

Reuters
·
Mar 02

Dyne Therapeutics Inc: Reaffirming Expected Cash Runway Into Q1 2028

THOMSON REUTERS
·
Mar 02